A robust ratio metric method for analysis of Zap-70 expression in chronic lymphocytic leukemia (CLL)
A robust ratio metric method for analysis of Zap-70 expression in chronic lymphocytic leukemia (CLL)
复制标题
DOI：
10.1002/cyto.b.20079
复制
发表时间：
2006-07-15
影响因子：
3.4
通讯作者：
Huang, Andjames
中科院分区：
文献类型：
--
作者：
Bakke, Antony C.;Purtzer, Zoe;Huang, Andjames
由于Zap-70在慢性淋巴细胞白血病（CLL）细胞中的表达与免疫球蛋白可变重链（IgVH）基因的体细胞突变的缺乏相关，因此已经提出将其作为疾病预后的替代标志物。然而，已发表的Zap-70表达研究使用了不同的商业抗体和分析策略。本研究旨在确定是否有任何策略可广泛应用于临床流式细胞术实验室，使用四种不同的商业抗体在37例CLL患者中测定Zap-70的表达。通过免疫表型分析沿着Zap-70表达鉴定T、NK和CLL细胞。根据表达Zap-70的CLL细胞的百分比和CLL细胞中Zap-70表达与T + NK细胞中Zap-70表达的比率分析数据。三种Zap-70抗体显示作为肿瘤细胞百分比的宽范围的Zap-70表达，而第四种抗体给出一致升高的结果。将Zap-70表达百分比与任何两种抗体进行比较，得到较差的相关性（r（2）= 0.45-0.63）。我们的结果表明，以前的分析策略是不可重复的。提出了比率度量，其给出了更好的相关性（r（2）高达0.95），并且将允许分离具有升高或降低的Zap-70表达的CLL患者。(c)2005年国际分析细胞学学会。
Since Zap-70 expression in chronic lymphocytic leukemia (CLL) cells correlates with a lack of somatic mutation of the immunoglobulin variable heavy chain (IgVH) genes, it has been proposed as a surrogate marker for disease prognosis. However, published studies of Zap-70 expression have used different commercial antibodies and analytic strategies. This study was undertaken to determine if any strategy was broadly applicable in a clinical flow cytometry laboratory.Expression of Zap-70 was determined in 37 CLL patients using four different commercial antibodies. T, NK, and CLL cells were identified by immunophenotyping along with Zap-70 expression. Data was analyzed in terms of both percent of CLL cells expressing Zap-70 and the ratio of Zap-70 expression in CLL cells compared to that in T + NK cells.Three Zap-70 antibodies showed wide ranges of Zap-70 expression as a percentage of tumor cells, while a fourth gave consistently elevated results. Comparing the percent Zap-70 expression with any two antibodies gave poor correlations (r(2) = 0.45-0.63). Our results indicated that the previous analytical strategies were not reproducible. A ratio metric is proposed, which gave better correlations (r(2) as high as 0.95) and would allow separation of CLL patients with elevated or decreased Zap-70 expression. (c) 2005 International Society for Analytical Cytology.